PUNE: Several Guillain-Barré Syndrome (GBS) patients are struggling with mobility issues, weeks after discharge from hospital ...

PUNE: The ninth casualty linked to Guillain-Barre Syndrome in Pune, a 34-year-old resident of Wagholi, showed symptoms that surprised his doctors. The patient had complained of loose motions for three ...

Patients with Guillain-Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness.

DEAR DR. ROACH: I am a 73-year-old female with atrial fibrillation (AFib) who recently had a pacemaker implant and has been doing well since. I also have a thyroid gland disorder, and I’m taking daily ...

NEW YORK, Oct. 18 (UPI) --A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus. The ...

ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg ...

Jess Thomson is a Newsweek Science Reporter based in London UK. Her focus is reporting on science, technology and healthcare. She has covered weird animal behavior, space news and the impacts of ...

After reaching the summit in a yearslong mission of introducing Takeda’s plasma-derived therapies (PDTs) to the market in its ...

Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. ANX005 has the potential to become the first FDA approved therapy for ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...